Huang Yu-Chuen, Chen Marcelo, Lin Ming-Wei, Chung Ming-Yi, Chang Yen-Hwa, Huang William Ji-Shian, Wu Tony T, Hsu Jong-Ming, Yang Stone, Chen Yi-Ming Arthur
Division of Preventive Medicine, Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Urology. 2007 May;69(5):996-1000. doi: 10.1016/j.urology.2007.02.014.
The CYP19 gene encodes aromatase--a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa).
Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%.
The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83).
The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.
CYP19基因编码芳香化酶，这是一种参与将雄烯二酮/睾酮转化为雌酮/雌二醇的关键酶。在本研究中，我们分析了CYP19基因的TCT插入（Ins）/缺失（Del）和TTTA重复多态性与前列腺癌（PCa）之间的关联。
使用配备GeneScan软件的自动测序仪，对244例PCa患者和261例年龄匹配的健康男性对照者外周血单个核细胞DNA中的CYP19基因多态性进行测定。I至IV期的分布分别为3.4%、23.8%、19.6%和53.2%。Gleason评分2至5分的占22.9%，6至7分的占53.2%，8至10分的占23.8%。
台湾PCa患者中TCT Del/Del基因型的频率（12.3%）显著高于对照组（5.4%；P = 0.015，优势比[OR] 2.43，95%置信区间[CI] 1.23至4.80）。纯合A1（七个TTTA重复）基因型个体患PCa的风险显著更高（OR 1.59，95% CI 1.04至2.44，P = 0.044）。对照组中Ins-A6（12个TTTA重复）单倍型的频率显著高于患者组（9.8%对6.1%，OR 0.61，95% CI 0.38至0.97）。纯合Del-A1双倍型男性患PCa的OR为2.31（95% CI 1.10至4.83）。
我们的研究结果表明，CYP19 TCT Del/Del基因型可能是PCa的一个易感标志物。具有Ins-A6单倍型的男性患PCa的风险较低。
